Market Place
Sourcing Support
Alnylam Announces Publication of Results from Phase 3 Study of Patisiran
25 Oct 2023 //
BUSINESSWIRE
FDA Blocks Alnylam’s Bid to Expand Onpattro Label
10 Oct 2023 //
BIOSPACE
Alnylam Stock Trading Halted Today
13 Sep 2023 //
BUSINESSWIRE
FDA questions efficacy of Alnylam`s patisiran in disabling ATTR-CM
12 Sep 2023 //
ENDPTS
Alnylam Announces Date of Planned FDA Advisory Committee Meeting for ONPATTRO
30 Jun 2023 //
BUSINESSWIRE
Alnylam Announces FDA Acceptance of Supplemental NDA for ONPATTRO
21 Feb 2023 //
BUSINESSWIRE
Alnylam to face FDA Adcomm for Onpattro`s ATTR-CM bid
21 Feb 2023 //
FIERCE PHARMA
Alnylam Submits sNDA to U.S. FDA for ONPATTRO for Cardiomyopathy
08 Dec 2022 //
BUSINESSWIRE
Alnylam`s new Onpattro data raise fresh doubts: analyst
03 Oct 2022 //
FIERCEPHARMA
Alnylam to Present Data from the APOLLO-B PIII Study of Patisiran in Patients
13 Sep 2022 //
BUSINESSWIRE
Alnylam Presents Positive Results from the APOLLO-B Phase 3 Study of Patisiran
08 Sep 2022 //
PRESS RELEASE
Alnylam Pharma Scores `Clean Hit` In Closely Watched Heart Study; Hits Record
04 Aug 2022 //
ENDPTS
Alnylam Reports Positive Topline Results from APOLLO-B PIII Study of Patisiran
03 Aug 2022 //
PRESS RELEASE
Alnylam`s high-stakes Onpattro heart trial posts partial win
03 Aug 2022 //
FIERCEPHARMA
Alnylam Pharmaceuticals Reports Q3 2021 Financial Results and Highlights
28 Oct 2021 //
BUSINESSWIRE
ONPATTRO Now Reimbursed in Canada For Treatment of hATTR
28 Sep 2021 //
BIOSPACE
Alnyam under federal investigation for Onpattro marketing
15 Apr 2021 //
FIERCE PHARMA
Alnylam Wins Prestigious Prix Galien Award for Best Biotechnology Product
30 Oct 2020 //
BUSINESSWIRE
Alnylam & Gen Sign Distribution Agreement in Turkey for ONPATTRO® (patisiran)
25 Mar 2020 //
BUSINESSWIRE
Alnylam`s Announces Initiation of APOLLO-B Phase 3 Study of Patisiran
16 Sep 2019 //
BUSINESSWIRE
Alnylam`s Onpattro back in the game against Ionis, thanks to NICE U-turn
09 Jul 2019 //
FIERCE PHARMA
Akcea steals march on Alnylam with NICE approval
17 Apr 2019 //
PMLIVE
BioWorld’s Top 10: Biggest newsmakers and trending stories of 2018
02 Jan 2019 //
BIOWORLD
5 Biopharma Trends to Watch in 2019
01 Jan 2019 //
GEN
Alnylam CEO talks politics, gene therapy and not becoming Pfizer
15 Dec 2018 //
BIOPHARMA DIVE
NICE reject two treatments for fatal, ultra-rare disease
13 Dec 2018 //
PHARMA FILE
Alnylam`s Onpattro sales look `disappointing` in early days of RNAi launch
20 Nov 2018 //
FIERCE PHARMA
Alnylam`s Onpattro (patisiran sodium) Receives Approval in Europe
31 Oct 2018 //
EMA
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
16 Oct 2018 //
XCONOMY
Alnylam Announces NDA Submission in Japan for ONPATTRO™ (patisiran sodium)
28 Sep 2018 //
BUSINESSWIRE
Alnylam Pharmaceuticals Could Use Some Straightforward Good News
27 Sep 2018 //
SEEKING ALPHA
Alnylam`s Exploratory Cardiac Endpoint Data from APOLLO Ph-3 Study of Patisiran
14 Sep 2018 //
BUSINESSWIRE
Novartis’ & Gilead’s CAR-Ts, Alnylam’s Onpattro and others rack up EU approvals
01 Sep 2018 //
FIERCE PHARMA
Alnylam’s RNA therapy Onpattro bags EU nod
01 Sep 2018 //
PHARMA TIMES
Pfizer`s tafamidis score still leaves `door open` for Alnylam rival: analysts
28 Aug 2018 //
FIERCE PHARMA
Approval, Labeling, Pricing, Competitor Data All Give Alnylam a Wild Ride
28 Aug 2018 //
SEEKING ALPHA
FDA rejects Akcea/Ionis’ rare disease drug Waylivra
28 Aug 2018 //
PHARMA TIMES
Xarelto flops, Pfizer’s tafamidis wins, Entresto’s early use and more
27 Aug 2018 //
FIERCE PHARMA
Pfizer eyes ATTR cardiomyopathy filing for tafamidis after acing phase 3 trial
27 Aug 2018 //
FIERCE BIOTECH
